Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.

Kanda Y, Kimura SI, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K; Japan Febrile Neutropenia Study Group.

J Clin Oncol. 2020 Jan 24:JCO1901916. doi: 10.1200/JCO.19.01916. [Epub ahead of print]

PMID:
31977270
2.

IgG4-related Disease with a Cardiac Mass.

Matsumura I, Mitsui T, Tahara K, Shimizu H, Yanagisawa K, Ishizaki T, Koiso H, Takizawa M, Yokohama A, Saitoh T, Hirato J, Murakami H, Handa H, Tsukamoto N.

Intern Med. 2020 Jan 17. doi: 10.2169/internalmedicine.4054-19. [Epub ahead of print]

3.

Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.

Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H.

Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709.

4.

Inhibition of the IL-18 Receptor Signaling Pathway Ameliorates Disease in a Murine Model of Rheumatoid Arthritis.

Nozaki Y, Ri J, Sakai K, Niki K, Kinoshita K, Funauchi M, Matsumura I.

Cells. 2019 Dec 18;9(1). pii: E11. doi: 10.3390/cells9010011.

5.

Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome.

Nakayama S, Morita Y, Espinoza JL, Rai S, Taniguchi Y, Taniguchi T, Miyake Y, Tanaka H, Ashida T, Matsumura I.

Ann Hematol. 2020 Feb;99(2):381-383. doi: 10.1007/s00277-019-03849-x. Epub 2019 Nov 25. No abstract available.

PMID:
31768673
6.

Case of progression to multisystem Langerhans cell histiocytosis with polyostotic and cutaneous involvement from recurrent single-system monostotic Langerhans cell histiocytosis.

Yanagihara S, Oiso N, Morita Y, Miyake Y, Kato M, Matsumura I, Kawada A.

J Dermatol. 2020 Jan;47(1):e4-e5. doi: 10.1111/1346-8138.15133. Epub 2019 Nov 2. No abstract available.

PMID:
31677174
7.

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

Int J Hematol. 2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. Epub 2019 Sep 19.

PMID:
31538327
8.

Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia.

Nakayama S, Morita Y, Espinoza JL, Rai S, Oyama Y, Taniguchi T, Miyake Y, Tanaka H, Matsumura I.

Leuk Lymphoma. 2019 Sep 18:1-3. doi: 10.1080/10428194.2019.1665665. [Epub ahead of print] No abstract available.

PMID:
31533519
9.

Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan.

Yoshida I, Tamura K, Miyamoto T, Shimokawa M, Takamatsu Y, Nanya Y, Matsumura I, Gotoh M, Igarashi T, Takahashi T, Aiba K, Kumagai K, Ishizawa K, Kurita N, Usui N, Hatake K.

In Vivo. 2019 Jul-Aug;33(4):1355-1362. doi: 10.21873/invivo.11611.

10.

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.

Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H, Minaga K, Kamata K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Enoki E, Inoue H, Matsumura I, Kudo M.

Intern Med. 2019 Jul 15;58(14):2029-2033. doi: 10.2169/internalmedicine.2495-18. Epub 2019 Apr 17.

11.

Intravascular Lymphoma Presenting as a Cavernous Sinus Tumor.

Kawai S, Okuda T, Fukui A, Sanada Y, Yoshikawa K, Morikawa M, Kuwahara M, Maenishi O, Morita Y, Izumoto S, Kato A, Matsumura I, Kusunoki S.

Intern Med. 2019 Jul 15;58(14):2085-2089. doi: 10.2169/internalmedicine.1828-18. Epub 2019 Mar 28.

12.

Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells.

Tanaka H, Espinoza JL, Fujiwara R, Rai S, Morita Y, Ashida T, Kanakura Y, Matsumura I.

Cells. 2019 Mar 8;8(3). pii: E226. doi: 10.3390/cells8030226.

13.

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators.

Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14.

PMID:
30762219
14.

Protective effect and mechanism of IL-10 on renal ischemia-reperfusion injury.

Sakai K, Nozaki Y, Murao Y, Yano T, Ri J, Niki K, Kinoshita K, Funauchi M, Matsumura I.

Lab Invest. 2019 May;99(5):671-683. doi: 10.1038/s41374-018-0162-0. Epub 2019 Jan 30.

PMID:
30700847
15.

Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality.

Rai S, Espinoza JL, Morita Y, Tanaka H, Matsumura I.

Front Immunol. 2019 Jan 9;9:3031. doi: 10.3389/fimmu.2018.03031. eCollection 2018.

16.

Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis.

Nozaki Y, Inoue A, Kinoshita K, Funauchi M, Matsumura I.

Mod Rheumatol. 2019 Mar 4:1-10. doi: 10.1080/14397595.2019.1572267. [Epub ahead of print]

PMID:
30676812
17.

Prediction of therapeutic responses with ultrasonography in RA patients treated with an anti-TNF drug: a retrospective cohort study.

Nozaki Y, Ri J, Sakai K, Shiga T, Inoue A, Nagare Y, Funauchi M, Matsumura I.

Immunol Med. 2018 Sep;41(3):129-135. doi: 10.1080/25785826.2018.1531192. Epub 2018 Nov 17.

PMID:
30618341
18.

Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome.

Nakayama S, Taniguchi T, Tanaka H, Espinoza JL, Rai S, Matsumura I.

Br J Haematol. 2019 Jan;184(2):122. doi: 10.1111/bjh.15733. Epub 2018 Dec 28. No abstract available.

PMID:
30592297
19.

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results.

Nozaki Y, Nagare Y, Ashida C, Tomita D, Okada A, Inoue A, Kinoshita K, Funauchi M, Matsumura I.

Biologics. 2018 Nov 27;12:171-182. doi: 10.2147/BTT.S187998. eCollection 2018.

20.

Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.

Li JF, Dai YT, Lilljebjörn H, Shen SH, Cui BW, Bai L, Liu YF, Qian MX, Kubota Y, Kiyoi H, Matsumura I, Miyazaki Y, Olsson L, Tan AM, Ariffin H, Chen J, Takita J, Yasuda T, Mano H, Johansson B, Yang JJ, Yeoh AE, Hayakawa F, Chen Z, Pui CH, Fioretos T, Chen SJ, Huang JY.

Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11711-E11720. doi: 10.1073/pnas.1814397115. Epub 2018 Nov 28.

21.

Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion.

Taniguchi T, Nakayama S, Morita Y, Rai S, Espinoza JL, Matsumura I.

Br J Haematol. 2019 Jan;184(2):121. doi: 10.1111/bjh.15689. Epub 2018 Nov 28. No abstract available.

PMID:
30485406
22.

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.

Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).

Ann Hematol. 2019 Jan;98(1):83-91. doi: 10.1007/s00277-018-3492-5. Epub 2018 Sep 24.

PMID:
30251205
23.

New Insights on the Pathogenesis of Takayasu Arteritis: Revisiting the Microbial Theory.

Espinoza JL, Ai S, Matsumura I.

Pathogens. 2018 Sep 6;7(3). pii: E73. doi: 10.3390/pathogens7030073. Review.

24.

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab.

Rai S, Tanaka H, Fujimoto K, Kumode T, Inoue H, Taniguchi Y, Morita Y, Espinoza JL, Tatsumi Y, Ashida T, Matsuoka R, Kikuti YY, Nakamura N, Matsumura I.

Cancers (Basel). 2018 Sep 3;10(9). pii: E304. doi: 10.3390/cancers10090304.

25.

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.

Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y; and the Japanese Adult Leukemia Study Group.

Leukemia. 2019 Feb;33(2):358-370. doi: 10.1038/s41375-018-0233-7. Epub 2018 Aug 9.

PMID:
30093681
26.

Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.

Nakayama S, Matsuda M, Adachi T, Sueda S, Ohashi Y, Awaji S, Hashimoto S, Matsumura I.

Platelets. 2019;30(5):637-645. doi: 10.1080/09537104.2018.1499889. Epub 2018 Jul 26.

PMID:
30047815
27.

Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.

Kato R, Hayashi H, Sano K, Handa K, Kumode T, Ueda H, Okuno T, Kawakami H, Matsumura I, Kudo M, Nakagawa K.

J Thorac Oncol. 2018 Dec;13(12):e239-e241. doi: 10.1016/j.jtho.2018.06.024. Epub 2018 Jul 12. No abstract available.

28.

Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry.

Nakaya A, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida SI, Uoshima N, Kawata E, Uchiyama H, Shimura Y, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, Shindo M, Tanaka H, Shimazaki C, Hino M, Kuroda J, Kanakura Y, Takaoari-Kondo A, Nomura S, Matsumura I; Kansai Myeloma Forum Investigators.

Leuk Res Rep. 2018 Jul 4;10:7-10. doi: 10.1016/j.lrr.2018.07.001. eCollection 2018.

29.

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M.

Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26.

30.

Tumor necrosis factor- and interleukin-6-producing high-grade B-cell lymphoma, not otherwise specified in the pleura.

Nakayama S, Matsuda M, Adachi T, Sueda S, Ueda K, Kawahara K, Ohashi Y, Awaji S, Hashimoto S, Matsumura I.

Leuk Res Rep. 2018 Jun 28;10:1-3. doi: 10.1016/j.lrr.2018.06.001. eCollection 2018.

31.

Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma.

Sueda S, Nakayama S, Adachi T, Ohashi Y, Awaji S, Hashimoto S, Matsumura I, Matsuda M.

Ann Hematol. 2019 Jan;98(1):235-236. doi: 10.1007/s00277-018-3426-2. Epub 2018 Jul 6. No abstract available.

PMID:
29978285
32.

Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report.

Serizawa K, Tanaka H, Morita Y, Taniguchi T, Ashida T, Matsumura I.

Front Oncol. 2018 Jun 5;8:204. doi: 10.3389/fonc.2018.00204. eCollection 2018.

33.

Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols.

Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group.

Support Care Cancer. 2018 Dec;26(12):4187-4198. doi: 10.1007/s00520-018-4292-0. Epub 2018 Jun 2.

PMID:
29860713
34.

[Giant hemophilic pseudotumors in brothers with non-severe hemophilia B].

Matsumura I, Yanagisawa K, Ogawa Y, Shimizu H, Ishizaki T, Mitsui T, Uchiumi H, Uchiyama Y, Matsumuto N, Handa H.

Rinsho Ketsueki. 2018;59(3):287-292. doi: 10.11406/rinketsu.59.287. Japanese.

PMID:
29618686
35.

Adult T cell leukemia/lymphoma with different pathological features in each tumor site.

Nakayama S, Matsuda M, Adachi T, Sueda S, Ohashi Y, Awaji S, Hashimoto S, Matsumura I.

Ann Hematol. 2018 Jun;97(6):1095-1096. doi: 10.1007/s00277-018-3272-2. Epub 2018 Feb 9. No abstract available.

PMID:
29427186
36.

[Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].

Matsumura I.

Rinsho Ketsueki. 2018;59(1):13-26. doi: 10.11406/rinketsu.59.13. Review. Japanese.

PMID:
29415932
37.

Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.

Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators.

Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29.

PMID:
29380179
38.

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y.

Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23.

PMID:
29362980
39.

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.

Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG.

Leuk Res. 2018 Mar;66:20-27. doi: 10.1016/j.leukres.2018.01.008. Epub 2018 Jan 17.

PMID:
29360622
40.

[Successful treatment of secondary graft failure with donor lymphocyte infusion in a post-allogeneic stem cell transplant acute myeloid leukemia patient].

Serizawa K, Ashida T, Taniguchi T, Taniguchi Y, Morita Y, Tanaka H, Shimada T, Tatsumi Y, Matsumura I.

Rinsho Ketsueki. 2017;58(12):2386-2391. doi: 10.11406/rinketsu.58.2386. Review. Japanese.

PMID:
29332871
41.

Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia.

Miyatake J, Inoue H, Serizawa K, Morita Y, Espinoza JL, Tanaka H, Shimada T, Tatsumi Y, Ashida T, Matsumura I.

Intern Med. 2018 May 15;57(10):1445-1453. doi: 10.2169/internalmedicine.9668-17. Epub 2018 Jan 11.

42.

Post-herpes zoster sarcoidosis as a recurrence.

Yamauchi K, Oiso N, Iwanaga T, Tatsumi Y, Matsumura I, Tohda Y, Kawada A.

J Dermatol. 2018 Jun;45(6):e150-e151. doi: 10.1111/1346-8138.14211. Epub 2018 Jan 9. No abstract available.

PMID:
29318641
43.

Lipopolysaccharide-Induced Acute Kidney Injury Is Dependent on an IL-18 Receptor Signaling Pathway.

Nozaki Y, Hino S, Ri J, Sakai K, Nagare Y, Kawanishi M, Niki K, Funauchi M, Matsumura I.

Int J Mol Sci. 2017 Dec 20;18(12). pii: E2777. doi: 10.3390/ijms18122777.

44.

Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease.

Kono M, Komeda Y, Sakurai T, Okamoto A, Minaga K, Kamata K, Hagiwara S, Inoue H, Enoki E, Matsumura I, Watanabe T, Kudo M.

J Crohns Colitis. 2018 Mar 28;12(4):499-502. doi: 10.1093/ecco-jcc/jjx170.

PMID:
29253109
45.

[Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study].

Ando K, Chou T, Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Okamoto S, Otsuka M, Matsumoto M, Iida S, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Terui Y.

Rinsho Ketsueki. 2017;58(11):2219-2226. doi: 10.11406/rinketsu.58.2219. Japanese.

PMID:
29212972
46.

Gastric microbiota: An emerging player in Helicobacter pylori-induced gastric malignancies.

Espinoza JL, Matsumoto A, Tanaka H, Matsumura I.

Cancer Lett. 2018 Feb 1;414:147-152. doi: 10.1016/j.canlet.2017.11.009. Epub 2017 Nov 11. Review.

PMID:
29138097
47.

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.

Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H.

Int J Hematol. 2018 Mar;107(3):327-336. doi: 10.1007/s12185-017-2353-7. Epub 2017 Oct 26.

PMID:
29076005
48.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
49.

Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.

Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I.

Int J Hematol. 2017 Nov;106(5):691-703. doi: 10.1007/s12185-017-2302-5. Epub 2017 Aug 5.

PMID:
28780601
50.

Longitudinal nosocomial outbreak of Pseudomonas fluorescens bloodstream infection of 2 years' duration in a coronary care unit.

Oba Y, Nakajima T, Ogida C, Kawanami M, Fujiwara M, Matsumura I.

Am J Infect Control. 2017 Aug 1;45(8):e75-e79. doi: 10.1016/j.ajic.2017.05.008. Epub 2017 Jun 21.

PMID:
28647051

Supplemental Content

Loading ...
Support Center